Donated organ as a source of cytomegalovirus in orthotopic liver transplantation
β Scribed by Dr. Sheena Sutherland; Paul Bracken; Tim G. Wreghitt; John O'Grady; Roy Y. Calne; Roger Williams
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 411 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The importance of the donated organ as a source of CMV was assessed in 120 patients following orthotopic liver transplant and the CMV infections that developed in these patients were graded by severity. Fortyβfour recipients were CMV antibody negative preβtransplant. Eighteen of these received organs from CMV antibody positive donors and 15 (83%) developed primary CMV infections, 13 (87%) of which were symptomatic. Twentyβsix received organs from CMV antibody negative donors and only 2 (8%) became CMV positive post transplant (P < 0.001). These data suggest that there would be a considerable advantage in matching CMV antibody negative recipients with negative donors. Fortyβfive percent of secondary infections were asymptomatic compared with 12% of primary infections, and only 11% became disseminated compared with 53% of primary infections. The secondary infections that followed transplantation of an organ from a CMV antibody positive donor were more likely to be symptomatic and were more severe than those in patients who received seronegative livers. Β© 1992 WileyβLiss, Inc.
π SIMILAR VOLUMES
Cytomegalovirus (CMV) is an important cause of morbidity and mortality in liver transplant recipients and several different strategies of CMV chemoprophylaxis are in practice. A cost-effective analysis was performed to compare these strategies. A hypothetical cohort of liver transplant recipients wa
Mortality of fulminant hepatic failure with standard supportive therapy is high (80 to 85%), but unfortunately most patients present to hospital already in Grade IV encephalopathy with severe liver dysfunction, and many have secondary organ damage. If seen earlier, during Grade III encephalopathy, r
The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (RΟͺ/DΟ©) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institutio